

Université de Poitiers

Faculté de Médecine et Pharmacie

ANNEE 2020

Thèse n°

MÉMOIRE DU DIPLÔME D'ÉTUDES SPÉCIALISÉES DE BIOLOGIE MÉDICALE (décret du 23 janvier 2003)

et

THÈSE POUR LE DIPLÔME D'ÉTAT DE DOCTEUR EN MÉDECINE (décret du 16 janvier 2004)

présentée et soutenue publiquement
le 21 septembre 2020 à Poitiers
par **Monsieur HUBERT Florent**

Les amibes libres favorisent la survie et la prolifération
de *Candida auris* dans l'eau

Composition du jury :

Président : - Madame le Professeur Rodier Marie-Hélène

Membres : - Madame le Professeur Imbert Christine
- Madame le Docteur Perraud Estelle

Directeur de thèse : Monsieur le Docteur Brunet Kévin

LISTE DES ENSEIGNANTS DE MEDECINE

Professeurs des Universités-Praticiens Hospitaliers

- BOULETI Claire, cardiologie (**absente jusque début mars 2020**)
- BRIDOUX Frank, néphrologie
- BURUCOA Christophe, bactériologie – virologie
- CHEZE-LE REST Catherine, biophysique et médecine nucléaire
- CHRISTIAENS Luc, cardiologie
- CORBI Pierre, chirurgie thoracique et cardio-vasculaire
- DAHYOT-FIZELIER Claire, anesthésiologie – réanimation
- DEBAENE Bertrand, anesthésiologie réanimation
- DEBIAIS Françoise, rhumatologie
- DROUOT Xavier, physiologie
- DUFOUR Xavier, Oto-Rhino-Laryngologie
- FAURE Jean-Pierre, anatomie
- FRASCA Denis, anesthésiologie-réanimation
- FRITEL Xavier, gynécologie-obstétrique
- GAYET Louis-Etienne, chirurgie orthopédique et traumatologique
- GERVAIS Elisabeth, rhumatologie
- GICQUEL Ludovic, pédopsychiatrie
- GILBERT Brigitte, génétique
- GOMBERT Jean-Marc, immunologie
- GOUJON Jean-Michel, anatomie et cytologie pathologiques
- GUILLEVIN Rémy, radiologie et imagerie médicale
- HAUET Thierry, biochimie et biologie moléculaire
- HOUETO Jean-Luc, neurologie
- INGRAND Pierre, biostatistiques, informatique médicale
- ISAMBERT Nicolas, cancérologie
- JAAFARI Nematollah, psychiatrie d'adultes
- JABER Mohamed, cytologie et histologie
- JAYLE Christophe, chirurgie thoracique t cardio-vasculaire
- KARAYAN-TAPON Lucie, cancérologie
- KEMOUN Gilles, médecine physique et de réadaptation (**en détachement**)
- KRAIMPS Jean-Louis, chirurgie générale
- LECLERE Franck, chirurgie plastique, reconstructrice
- LECRON Jean-Claude, biochimie et biologie moléculaire
- LELEU Xavier, hématologie
- LEVARD Guillaume, chirurgie infantile
- LEVEQUE Nicolas, bactériologie-virologie
- LEVEZIEL Nicolas, ophtalmologie
- MACCHI Laurent, hématologie
- MCHEIK Jiad, chirurgie infantile
- MEURICE Jean-Claude, pneumologie
- MIGEOT Virginie, santé publique
- MILLOT Frédéric, pédiatrie, oncologie pédiatrique
- MIMOZ Olivier, anesthésiologie – réanimation
- NEAU Jean-Philippe, neurologie
- ORIOT Denis, pédiatrie
- PACCALIN Marc, gériatrie
- PERAULT Marie-Christine, pharmacologie clinique
- PERDRISOT Rémy, biophysique et médecine nucléaire
- PIERRE Fabrice, gynécologie et obstétrique
- PRIES Pierre, chirurgie orthopédique et traumatologique
- RAMMAERT-PALTRIE Blandine, maladies infectieuses
- RICHER Jean-Pierre, anatomie
- RIGOARD Philippe, neurochirurgie

- ROBERT René, réanimation
- ROBLOT France, maladies infectieuses, maladies tropicales
- ROBLOT Pascal, médecine interne
- RODIER Marie-Hélène, parasitologie et mycologie
- SAULNIER Pierre-Jean, thérapeutique
- SCHNEIDER Fabrice, chirurgie vasculaire
- SILVAIN Christine, hépato-gastro-entérologie
- TASU Jean-Pierre, radiologie et imagerie médicale
- THIERRY Antoine, néphrologie
- THILLE Arnaud, réanimation
- TOUGERON David, gastro-entérologie
- WAGER Michel, neurochirurgie
- XAVIER Jean, pédopsychiatrie

Maîtres de Conférences des Universités-Praticiens Hospitaliers

- ALBOUY-LLATY Marion, santé publique
- BEBY-DEFAUX Agnès, bactériologie – virologie
- BEN-BRIK Eric, médecine du travail (**en détachement**)
- BILAN Frédéric, génétique
- BOISSON Matthieu, anesthésiologie-réanimation et médecine péri-opératoire
- BOURMEYSTER Nicolas, biologie cellulaire
- CASTEL Olivier, bactériologie - virologie – hygiène
- CAYSSIALS Emilie, hématologie
- COUDROY Rémy, réanimation
- CREMNITER Julie, bactériologie – virologie
- DIAZ Véronique, physiologie
- FROUIN Eric, anatomie et cytologie pathologiques
- GARCIA Magali, bactériologie-virologie
- JAVAUGUE Vincent, néphrologie
- KERFORNE Thomas, anesthésiologie-réanimation et médecine péri-opératoire
- LAFAY Claire, pharmacologie clinique
- MARTIN Mickaël, médecine interne
- PALAZZO Paola, neurologie
- PERRAUD Estelle, parasitologie et mycologie
- SAPANET Michel, médecine légale
- THUILLIER Raphaël, biochimie et biologie moléculaire

Professeur des universités

- PELLERIN Luc, biochimie et biologie moléculaire

Professeur des universités de médecine générale

- BINDER Philippe

Professeurs associés de médecine générale

- BIRAULT François
- FRECHE Bernard
- MIGNOT Stéphanie
- PARTHENAY Pascal
- VALETTE Thierry
- VICTOR-CHAPLET Valérie

Maîtres de Conférences associés de médecine générale

- AUDIER Pascal
- ARCHAMBAULT Pierrick
- BRABANT Yann

Enseignants d'Anglais

- DEBAIL Didier, professeur certifié

Professeurs émérites

- ALLAL Joseph, thérapeutique (08/2020)
- BATAILLE Benoît, neurochirurgie (08/2020)
- CARRETIER Michel, chirurgie générale (08/2021)
- DORE Bertrand, urologie (08/2020)
- GIL Roger, neurologie (08/2020)
- GOMES DA CUNHA José, médecine générale (08/2021)
- GUILHOT-GAUDEFFROY François, hématologie et transfusion (08/2020)
- HERPIN Daniel, cardiologie (08/2020)
- KITZIS Alain, biologie cellulaire (16/02/2021)
- MARECHAUD Richard, médecine interne (24/11/2020)
- MAUCO Gérard, biochimie et biologie moléculaire (08/2021)
- RICCO Jean-Baptiste, chirurgie vasculaire (08/2020)
- SENON Jean-Louis, psychiatrie d'adultes (08/2020)
- TOUCHARD Guy, néphrologie (08/2021)

Professeurs et Maîtres de Conférences honoraires

- AGIUS Gérard, bactériologie-virologie
- ALCALAY Michel, rhumatologie
- ARIES Jacques, anesthésiologie-réanimation
- BABIN Michèle, anatomie et cytologie pathologiques
- BABIN Philippe, anatomie et cytologie pathologiques
- BARBIER Jacques, chirurgie générale (ex-émérite)
- BARRIERE Michel, biochimie et biologie moléculaire
- BECQ-GIRAUDON Bertrand, maladies infectieuses, maladies tropicales (ex-émérite)
- BEGON François, biophysique, médecine nucléaire
- BOINOT Catherine, hématologie – transfusion
- BONToux Daniel, rhumatologie (ex-émérite)
- BURIN Pierre, histologie
- CASTETS Monique, bactériologie -virologie – hygiène
- CAVELLIER Jean-François, biophysique et médecine nucléaire
- CHANSIGAUD Jean-Pierre, biologie du développement et de la reproduction
- CLARAC Jean-Pierre, chirurgie orthopédique
- DABAN Alain, oncologie radiothérapie (ex-émérite)
- DAGREGORIO Guy, chirurgie plastique et reconstructrice
- DESMAREST Marie-Cécile, hématologie
- DEMANGE Jean, cardiologie et maladies vasculaires
- EUGENE Michel, physiologie (ex-émérite)
- FAUCHERE Jean-Louis, bactériologie-virologie (ex-émérite)
- FONTANEL Jean-Pierre, Oto-Rhino Laryngologie (ex-émérite)
- GRIGNON Bernadette, bactériologie
- GUILLARD Olivier, biochimie et biologie moléculaire
- GUILLET Gérard, dermatologie
- JACQUEMIN Jean-Louis, parasitologie et mycologie médicale
- KAMINA Pierre, anatomie (ex-émérite)
- KLOSSEK Jean-Michel, Oto-Rhino-Laryngologie
- LAPIERRE Françoise, neurochirurgie (ex-émérite)
- LARSEN Christian-Jacques, biochimie et biologie moléculaire
- LEVILLAIN Pierre, anatomie et cytologie pathologiques
- MAIN de BOISSIERE Alain, pédiatrie
- MARCELLI Daniel, pédopsychiatrie (ex-émérite)
- MARILLAUD Albert, physiologie
- MENU Paul, chirurgie thoracique et cardio-vasculaire (ex-émérite)
- MORICHAU-BEAUCHANT Michel, hépato-gastro-entérologie
- MORIN Michel, radiologie, imagerie médicale
- PAQUEREAU Joël, physiologie
- POINTREAU Philippe, biochimie
- POURRAT Olivier, médecine interne (ex-émérite)
- REISS Daniel, biochimie
- RIDEAU Yves, anatomie
- SULTAN Yvette, hématologie et transfusion
- TALLINEAU Claude, biochimie et biologie moléculaire
- TANZER Joseph, hématologie et transfusion (ex-émérite)
- TOURANI Jean-Marc, oncologie
- VANDERMARCO Guy, radiologie et imagerie médicale



UNIVERSITE DE POITIERS

Faculté de Médecine et de Pharmacie



Année universitaire 2019-2020

PHARMACIE

Professeurs

- COUET William, pharmacie clinique PU-PH
- DUPUIS Antoine, pharmacie clinique PU-PH
- MARCHAND Sandrine, pharmacocinétique PU-PH
- RAGOT Stéphanie, santé publique PU-PH

- CARATO Pascal, chimie thérapeutique PR
- FAUCONNEAU Bernard, toxicologie PR
- GUILLARD Jérôme, pharmacochimie PR
- IMBERT Christine, parasitologie PR
- OLIVIER Jean Christophe, galénique PR
- PAGE Guylène, biologie cellulaire PR
- RABOUAN Sylvie, chimie physique, chimie analytique PR
- SARROUILHE Denis, physiologie PR
- SEGUIN François, biophysique, biomathématiques PR

Maîtres de Conférences

- BARRA Anne, immunologie-hématologie MCU-PH
- THEVENOT Sarah, hygiène et santé publique MCU-PH

- BARRIER Laurence, biochimie MCF
- BODET Charles, bactériologie MCF
- BON Delphine, biophysique MCF
- BRILLAULT Julien, pharmacocinétique, biopharmacie MCF
- BUYCK Julien, microbiologie, MCF
- CHARVET Caroline, physiologie MCF
- CHAUZY Alexia, pharmacologie fondamentale et thérapeutique MCF
- DEBORDE-DELAGE Marie, sciences physico-chimiques MCF
- DELAGE Jacques, biomathématiques, biophysique MCF
- FAVOT-LAFORGE Laure, biologie cellulaire et moléculaire MCF
- GIRARDOT Marion, biologie végétale et pharmacognosie, MCF

- GREGOIRE Nicolas, pharmacologie MCF
- HUSSAIN Didja, pharmacie galénique MCF
- INGRAND Sabrina, toxicologie MCF
- MARIVINGT-MOUNIR Cécile pharmacochimie MCF
- PAIN Stéphanie, toxicologie MCF
- RIOUX BILAN Agnès, biochimie MCF
- TEWES Frédéric, chimie et pharmacochimie MCF
- THOREAU Vincent, biologie cellulaire MCF
- WAHL Anne, chimie analytique MCF

Maîtres de Conférences Associés - officine

- DELOFFRE Clément, pharmacien
- ELIOT Guillaume, pharmacien
- HOUNKANLIN Lydwin, pharmacien

Enseignants d'anglais

- DEBAIL Didier

Remerciements

A Madame le Professeur Marie-Hélène RODIER,

Je vous remercie de me faire l'honneur de présider mon jury de thèse. Merci pour votre aide et votre expertise qui ont été indispensables à l'étude. Veuillez trouver dans ce travail le témoignage de ma reconnaissance et de mon profond respect.

A Madame le Professeur Christine IMBERT,

Je vous remercie de me faire l'honneur de juger mon travail. Veuillez trouver ici l'expression de ma sincère gratitude et de mon profond respect.

A Madame le Docteur Estelle PERRAUD,

Je te remercie d'avoir accepté de faire partie de ce jury ainsi que pour ton aide. Tu trouveras ici l'expression de ma sincère gratitude et de toute mon estime.

A Monsieur le Docteur Kévin BRUNET,

Je te remercie de m'avoir fait confiance en me proposant ce travail de thèse. Merci pour tes précieux conseils, tes compétences scientifiques et pour tout le temps que tu m'as consacré. Travailler à tes côtés fût très enrichissant.

Aux biologistes et techniciens du CHU de Poitiers et du CH de Niort

Merci pour la qualité de la formation et pour votre bienveillance.

A mes co-internes, et tout particulièrement

Vincent brillant photographe de levures. **Clémence** et **Simon** pour avoir « donné sa chance à la biochimie ». **Matthieu** pour mon initiation aux sketches des « Inconnus ». Sans oublier **Emilie**, **Rémi**, **Luc**, **Andy**, **Anaïs** et **Caroline** pour ces semestres inoubliables.

A mes amis de la Fac, du Lycée et du Collège, et notamment

Alban et **Momo** qui me font l'honneur et le privilège, malgré la distance, d'être présent à ma soutenance.

A ma famille,

Mes parents, que je ne remercierai jamais assez pour l'amour, le soutien et les valeurs que vous m'avez transmis. **Julien, Sophie et Jordan** pour tous ces fabuleux moments passés et à venir. **Dom et Annick** pour les relectures de mon manuscrit et votre soutien.

Enfin et surtout, à Céline,

Pour le bonheur partagé au quotidien depuis les bancs de la fac. Merci de m'avoir fait don de notre magnifique et merveilleuse fille, **Clémence**.

Sommaire

Liste des abréviations	8
Abstract	9
Introduction	11
Materials and methods	14
Strains and cultures conditions.....	14
FLA supernatants	14
Cocultivation of FLA and yeasts.....	14
Cocultivation of FLA supernatant and yeasts	15
Transmission electron microscopy analysis	15
Statistical analysis	16
Results	17
Presence of <i>C. auris</i> does not affect the number of FLA trophozoites.	17
<i>C. albicans</i> survival is differently impacted according to FLA species.....	18
FLA supernatants and trophozoites promote <i>C. auris</i> survival and proliferation.....	20
<i>C. auris</i> is found internalized and undigested in FLA trophozoites.....	22
Discussion	23
Acknowledgements	26
References	27
Résumé	33
SERMENT	34

Liste des abréviations

ATCC	American Type Culture Collection
CFU	Colony-Forming Unit
DUWL	Dental Unit Waterlines
FLA	Free Living Amoeba
MALDI-TOF MS	Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass Spectrometry
MET	Microscope Électronique à Transmission
MOI	Multiplicity Of Infection
PYG	Peptone, Yeast extract, Glucose
PYNFH	Peptone, Yeast extract, Nucleic acid, Folic acid, Hemin
TEM	Transmission Electron Microscopy

Abstract

Free-living amoebae promote *Candida auris* survival and proliferation in water

Introduction

Candida species are responsible for life-threatening infections in immunocompromised patients. Among them, *Candida auris* is an emerging species discovered in 2009 with recent outbreaks reported worldwide. Its ability to be resistant to most systemic antifungal classes, its identification issues and its capacity to persist in a hospital environment, have led to health concerns. Currently, data about environmental reservoirs are limited but remain essential in control of *C. auris* spread. The aim of our study was to explore the interactions between *C. auris* and two free-living amoeba (FLA) species potentially found in the same environment.

Materials and methods

C. auris was incubated with *Acanthamoeba castellanii* or *Vermamoeba vermiformis* trophozoites or their culture supernatants, in filtered hospital water at 37°C. The number of amoeba trophozoites and yeasts was determined at 48 h, 120 h and 168 h of cocultivation, and transmission electron microscopy (TEM) was performed after 48h. In order to compare the results to another yeast species, same experiments of cocultivation have been carried out with *Candida albicans*.

Results

While *C. albicans* and *C. auris* were not able to survive alone in water, supernatants of the two FLA species promoted yeasts survival and proliferation. *C. albicans* was destroyed by *A. castellanii* trophozoites but survived in the presence of *V. vermiformis* trophozoites. In contrast to *C. albicans*, *C. auris* was able to survive and proliferate in contact with *A. castellanii* or *V. vermiformis* trophozoites. Intact internalization of *C. auris* within both FLA species was also evidenced by TEM.

Conclusion

An environmental reservoir of *C. auris* can therefore be considered through FLAs and contamination of the hospital water networks would consequently be possible.

Keywords: *Candida auris*; Free-living amoeba; hospital tap water; outbreaks

Introduction

Candidiasis are invasive infections due to fungi belonging to *Candida* species (1). Though *Candida albicans* is the leading species involved, non-*albicans* candidemia have been on the uprise for many years (2). Increasing prevalence of colonization and infection with non-*albicans Candida* species may result from increasing use of antifungal agents such as fluconazole (3,4). Among these non-*albicans* species, a new one, *Candida auris*, was recently reported. This yeast was first described in Japan in a patient's ear canal in 2009 (5). In the same year, its pathogenicity was highlighted with three cases of candidemia identified at three university hospitals in South Korea (6). Subsequently, *C. auris* has been isolated from several body localizations in multiple countries on five continents (7), and implicated, similarly to other *Candida* species, in invasive infections associated with high mortality (8–10). Whole-genome sequencing revealed genetically distinct clades of this fungus on different continents and subcontinents, including East Asia, South Asia, South America, and Southern Africa (11). That suggests near-simultaneous emergence of *C. auris* rather than recent spread from a single source. It may be related to new or increasing antifungal selection in humans, animals, or in the environment (12).

One of the issues with *C. auris* is its ability to resist to antifungal drugs. Only three drug classes are available for systemic treatment of *Candidiasis*: azoles (fluconazole, itraconazole, isavuconazole, posaconazole, and voriconazole), polyenes (amphotericin B and its lipid formulations) and echinocandins (anidulafungin, caspofungin, and micafungin). An analysis of fifty-four clinical isolates of *C. auris* isolated from five countries (Pakistan, India, South Africa, Venezuela and Japan), from 2012 to 2015, found 93% of strains resistant to fluconazole, 35% resistant to amphotericin B, and 7% resistant to echinocandins. Moreover, 41% were resistant to 2 antifungal classes and 4% resistant to the 3 classes (11).

Another issue is identification of the yeast. Until recently, it was not identifiable by phenotypical method or matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). In fact, *C. auris* was misidentified as *Candida haemulonii*, *Candida famata* or *Rhodotorula glutinis* (13). A recent update of the MALDI-TOF MS libraries enables more reliable identification (14).

Furthermore, *C. auris* can cause outbreaks. Its diffusion in hospital environments appears superior to that of other *Candida* species. A large-scale outbreak between April 2015 and July 2016 involving 50 patients was reported in a cardiothoracic intensive care unit in London (15). The origin of this outbreak was linked to the persistence of the yeast on skin-surface axillary temperature probes. Several authors have demonstrated that *C. auris* can survive and persist on dry and non-porous surfaces for some weeks (16). In addition, frequently used detergents such as quaternary ammonium show poor activity against *C. auris* (17). The Control Disease Center of Atlanta specified that an Environmental Protection Agency-registered hospital-grade disinfectant effective against *Clostridium difficile* spores must be used for *C. auris* (18).

The reservoir of *C. auris* is not presently known and represents an important focus of research aimed at effectively reducing infectious risk. Environment could be the reservoir of *C. auris* and it must be investigated.

Free living amoebae (FLAs) are saprophytic and ubiquitous protozoa found in domestic water supplies, wells, dental irrigation units, hospital water supplies, or air conditioning units (19–21). They present a two-stage life, switching between a trophozoite form (active) and a cyst form (latent), which resists in hostile environmental conditions such as nutrient depletion, osmotic stress, temperature changes, or pH changes (22). Among FLAs, *Acanthamoeba castellanii* is a commonly species found as a saprophyte in the ear, nose and throat sphere in humans (23), and can also lead to serious corneal infection, primarily in contact lens wearers (24). *Vermamoeba vermiformis*, another FLA species, has only rarely been isolated in human pathology. However, it has been frequently found in natural aquatic environments or recreational waters such as swimming pools (25) and even in bottled mineral water (26). *V. vermiformis* has been more frequently isolated than *Acanthamoeba spp.* from hospital water (27).

It is recognized that FLA can interact with a variety of microorganisms including bacteria, viruses, and fungi (28). This association, when involving human pathogens, can have a significant health impact. For example, many dental procedures produce aerosols that may be contaminated by microorganisms hosted by FLAs forming biofilms in dental unit waterlines (DUWL) (32,33). Some case reports found in the literature have highlighted a link between contaminated DUWL exposure and infection (30–32). In the same way, *V. vermiformis* and *A. castellanii* may serve as hosts for pathogenic bacteria such as *Legionella pneumophila* (33).

Infected FLAs are found in hospital water networks leading to protection of this bacterium from water treatment, and may lead to *L. pneumophila* outbreaks (34,35). Another example is the relationships between FLAs and *C. albicans* which have previously been reported with *V. vermiformis* (36) and *A. castellanii* (37).

Due to the capacity of FLAs to promote the growth of microorganisms and interact with other *Candida* species, we have hypothesized that FLAs can lead to the proliferation and survival of *C. auris* in environmental and hospital water. The aim of this study was then to investigate *in vitro* interactions in water between *C. auris* and FLAs, and to compare them with interactions between these protists and the nosocomial yeast *C. albicans*.

Materials and methods

Strains and cultures conditions

The free living-amoeba (FLAs) used in this study were *Acanthamoeba castellanii* (ATCC 30234) and *Vermamoeba vermiformis* (ATCC 50256). FLAs were grown in 150 cm² tissue culture flasks at 27°C, in PYNFH broth for *V. vermiformis* and in PYG medium for *A. castellanii*, as previously described (38). When cells formed a monolayer, two washes were performed with filtered (0.22 µm) hospital tap water. Trophozoites were then harvested in 15 mL of this tap water and diluted for a final concentration of 5×10^5 trophozoites/mL.

The yeast strains used in this study were *Candida auris* (clinical strain, kindly provided by Dr E. Bailly, Tours Hospital, France) and *Candida albicans* (ATCC 14053). Yeasts were grown on Sabouraud agar at 37°C, for 24 h, then diluted in filtered hospital tap water to final sample concentration of 1.5×10^5 yeasts/mL.

FLA supernatants

A. castellanii and *V. vermiformis* were incubated in 150 cm² culture flasks containing 10 mL of hospital-filtered tap water. After 3 days at 27°C, the incubation medium was centrifuged (10 min, 800 g). Resulting supernatant was used for experiments.

Cocultivation of FLA and yeasts

100 µL of FLAs at 5×10^5 trophozoites/mL were distributed in a 96-well microplate and incubated for 2 hours at 37°C to promote adherence. Then, 100 µL of yeast suspension (1.5×10^5 yeasts/mL) was added leading to multiplicity of infection (MOI) of 0.3, and incubation was performed at 37 ° C.

At 48 h, 120 h and 168 h, FLAs viable trophozoites number was evaluated using Trypan Blue with KOVA hemocytometer.

After 48 h, 120 h and 168 h of incubation, serial dilutions of the cocultures were plated on CAN2 chromogenic medium (bioMérieux, Lyon, France) and incubated at 37°C during 48h

to evaluate the yeasts' colony-forming units (CFU). Controls were carried out by incubating yeasts in filtered tap water without FLA.

Experiments were performed for four combinations: *A. castellanii* and *C. albicans*, *A. castellanii* and *C. auris*, *V. vermiformis* and *C. albicans*, and *V. vermiformis* and *C. auris*. They were carried out in two independent experiments in triplicate.

Cocultivation of FLA supernatant and yeasts

In order to study indirect interactions between FLA and *Candida spp.*, the same experiments as those previously described were performed, but the 100 µL of FLA trophozoites were replaced by 100 µL of FLA supernatants. The two experiments were performed independently in triplicate.

Transmission electron microscopy analysis

FLA were cultured in 150 cm² tissue culture flasks at 27°C as previously described. When cells formed a monolayer, two washes were performed with hospital filtered tap water. Yeasts were then added to obtain a concentration of 1.5×10^5 yeast/mL.

After 48 h of incubation at 37°C, co-culture samples were centrifuged (5 min, 500g), supernatant was removed and pellet was fixed for 1 h with 2.5% glutaraldehyde in 1 mol/L phosphate buffer, pH 7.1. After phosphate buffered saline washes, pellet was post-fixed for 45 min in 1% osmium tetroxide in phosphate buffer. Dehydration was carried out using successive incubations of increasing ethanol concentrations (from 70 to 100%). Pellet was then suspended in 100% ethanol and centrifuged at 10,000 rpm for 10 min. Pellet was included in epon epoxy resin and after 24 h of polymerization, 70 nm sections were performed using an ultramicrotome UC6 (Leica). Uranyl acetate (2% in 70% ethanol) and lead citrate were used as contrasting agents for electron microscopy (JEOL 1010 at 80 kV). TEM was recorded using Quemesa camera with iTem® software (Olympus).

Statistical analysis

For statistical analysis, non-parametrical non-matching test of Mann-Whitney and Kruskal-Wallis, and non-parametrical matching test of Wilcoxon were used. They were carried out using GraphPad Prism® 8.0.1 software.

Results

Presence of *C. auris* does not affect the number of FLA trophozoites.

The number of viable amoebae trophozoites was evaluated at 48 h, 120 h and 168 h. For *A. castellanii* (Figure 1), the number of trophozoites was not significantly different between wells containing trophozoites alone and wells containing cocultures of trophozoites and *C. auris* or trophozoites and *C. albicans* ($p = 0.847$). Compared to the initial inoculum, a significant decrease of trophozoites was evidenced for all conditions ($p < 0.05$).




Figure 1: Viability of *Acanthamoeba castellanii* trophozoites alone and in co-cultivation with *Candida albicans* or *Candida auris*. *A. castellanii* trophozoites (5×10^5 trophozoites/mL) were incubated alone, with *C. albicans* (1.5×10^5 CFU/mL) or *C. auris* (1.5×10^5 CFU/mL) in tap-water at 37°C. At 48 h, 120 h and 168 h, *A. castellanii* trophozoites number was evaluated. *tropho.*: trophozoites.

The same results were highlighted for *V. vermiformis* (Figure 2), there was no significant difference between the three conditions (trophozoites alone, trophozoites and *C. auris*, trophozoites and *C. albicans*) ($p = 0.888$) and a significant decrease was evidenced compared to initial inoculum ($p < 0.05$).




Figure 2: Viability of *Vermamoeba vermiformis* trophozoites alone and in co-cultivation with *Candida albicans* or *Candida auris*. *V. vermiformis* trophozoites (5×10^5 trophozoites/mL) were incubated alone, with *C. albicans* (1.5×10^5 CFU/mL) or *C. auris* (1.5×10^5 CFU/mL) in tap-water at 37°C. At 48 h, 120 h and 168 h, *V. vermiformis* trophozoites number was evaluated. *tropho.*: trophozoites.

***C. albicans* survival is differently impacted according to FLA species.**

C. albicans was not able to grow in filtered water without FLA or FLA supernatants (Figure 3).

When this yeast was incubated with *A. castellanii* trophozoites, the number of fungal CFUs was very low with 47 CFU/mL at 48 h and 120 h and no fungal growth recovered after 168 h of cocultivation (Figure 3). However, after incubation in *A. castellanii* supernatant, the number of CFUs was significantly higher ($p < 0.05$), with 3×10^3 CFU/mL at 48h, 1.3×10^5 CFU/mL at 120h and 1.5×10^5 CFU/mL at 168h (Figure 3), with significant increased growth between 48 h and 120 h ($p < 0.05$).

In contrast, when *C. albicans* was incubated with *V. vermiformis* trophozoites, a high number of CFUs was reported with 3×10^4 CFU/mL, 2×10^5 CFU/mL, and 10^6 CFU/mL at 48 h, 120 h and 168 h respectively. The number of fungal CFUs was also high in the presence of *V. vermiformis* supernatant with 7×10^3 CFU/mL, 6×10^4 CFU/mL and 10^5 CFU/mL at 48h, 120h and 168h respectively. Significant growth was highlighted between 48 h and 120 h with FLA trophozoites ($p < 0.05$) or FLA supernatant ($p < 0.05$).




Figure 3: Number of *Candida albicans* CFUs in co-cultivation with FLA trophozoites or FLA supernatant. *C. albicans* (1.5×10^5 CFU/mL) was incubated with *A. castellanii* or *V. vermiformis* trophozoites (5×10^5 CFU/mL) or *A. castellanii* or *V. vermiformis* supernatant in tap-water at 37°C. At 48 h, 120 h and 168 h cocultures were plated and incubated at 37°C during 48 h to evaluate yeasts' CFUs. Experiment was performed in two independent experiments in triplicate. Tropho.: trophozoites ; Supern.: supernatant. * *p* < 0.05

FLA supernatants and trophozoites promote *C. auris* survival and proliferation.

As for *C. albicans*, *C. auris* was not able to grow in filtered water without FLA or FLA supernatants (Figure 4).

When *C. auris* was incubated with *A. castellanii* trophozoites, a high number of CFUs was reported with 2×10^4 CFU/mL, 2×10^5 CFU/mL and 10^5 CFU/mL at 48 h, 120 h and 168 h respectively (Figure 4). When *C. auris* was incubated with *A. castellanii* supernatant, the same behavior was observed with 2×10^5 CFU/mL, 7×10^5 CFU/mL and 3×10^5 CFU/mL at 48 h, 120 h and 168 h respectively (Figure 4). Moreover, significant growth was highlighted between 48 h and 120 h with FLA trophozoites ($p < 0.05$) or FLA supernatant ($p < 0.05$).

When *C. auris* was incubated with *V. vermiformis* trophozoites, the number of CFUs was 3×10^5 CFU/mL, 2×10^6 CFU/mL and 1×10^7 CFU/mL at 48 h, 120 h and 168 h respectively (Figure 4). When *C. auris* was incubated with *V. vermiformis* supernatant, the same behavior was observed with 10^5 CFU/mL, 7×10^6 CFU/mL and 3×10^6 CFU/mL at 48 h, 120 h and 168 h respectively. As for *A. castellanii*, significant growth was highlighted between 48 h and 120 h with FLA trophozoite ($p < 0.05$) or FLA supernatant ($p < 0.05$).




Figure 4: Number of *Candida auris* CFUs in co-cultivation with FLA trophozoites or FLA supernatant. *C. auris* (1.5×10^5 CFU/mL) was incubated with *A. castellanii* or *V. vermiformis* trophozoites (5×10^5 CFU/mL) or *A. castellanii* or *V. vermiformis* supernatant in tap-water at 37°C. At 48 h, 120 h and 168 h cocultures were plated and incubated at 37°C during 48 h to evaluate yeast' CFUs. Experiment was performed in two independent experiments in triplicate. *Tropho.*: trophozoites ; *Supern.*: supernatant.

***C. auris* is found internalized and undigested in FLA trophozoites.**

In order to visualize interaction between *C. auris* and *V. vermiformis* or *A. castellanii*, co-cultivations were incubated for 2 days at 37°C and TEM was performed. *C. auris* was found internalized in both amoeba species (Figure 5). Most of blastospores were found whole and undigested in phagocytosis vacuoles (Figure 5A, 5B and 5C). No digestion process was highlighted and, some FLA contained several yeasts (Figure 5 A and 5B). Pseudopodia were visible on some pictures (Figure 5D).




Figure 5: Transmission electron microscopy of *Candida auris* in cocultivation with FLA trophozoites. *C. auris* (1.5×10^5 CFU/mL) was incubated with *A. castellanii* trophozoites (A, B) or *V. vermiformis* trophozoites (C, D) at 37°C. After 48 h, coculture samples were fixed for MET analysis.

Discussion

Elucidation of *C. auris* reservoir, a new multi-resistant pathogen producing severe infection, may help to prevent dissemination. We have hypothesized that *C. auris* could survive and proliferate in water through interactions with FLAs. In this study, we conducted experiments to investigate interactions between two species of FLA and *C. auris*.

The number of amoeba trophozoites was evaluated at different times of cocultivation to determine the impact of *Candida spp.* on FLA trophozoites (Figures 1 and 2). For both species of FLA, there were no significant differences between groups. The number of amoeba trophozoites was similar between trophozoites alone and trophozoites in cocultures with *C. albicans* or *C. auris*. It would seem that, unlike some bacteria (39,40), these yeasts did not present an adverse effect on FLA. Interactions in the environment could consequently be possible since it is not deleterious to amoebae. Compared to the starting inoculum, 29% of amoeba trophozoites were still present at 48 h and about 12% at 168 hours. The significant overall decrease could be related to the lack of nutrients in the wells in our experimental conditions. However, due to the large number of amoeba trophozoites still present at 168 h, interactions with yeasts remained possible.

In our experimental conditions, *C. albicans* and *C. auris* seemed not able to survive in filtered (0.22 µm) hospital tap water at 37°C. For *C. albicans*, this was previously demonstrated, in the study conducted by Barbot *et al.* in 2012 (36). The authors showed that filtered tap water is not an appropriate environment. The same behavior was observed with *C. auris* in our study. Filtered tap water is a poor nutrient medium and may not be conducive to *Candida* planktonic culture proliferation. However, some *Candida* species, especially *C. auris*, have the ability to produce biofilm on different types of surfaces (41,42). It is therefore not excluded that even without FLA, *C. auris* was able to resist on surfaces, in biofilm condition, in contact with water under real conditions.

Our results show that supernatants of both FLA species leads to survival and proliferation of *C. albicans* and *C. auris*. This same behavior has been found for several other microorganisms such as *Salmonella enterica* serovar *Typhi* (43), *Acinetobacter baumannii* (44), *Mycobacterium Smegmatis* (45) or *Fusarium oxysporum* (46). FLAs secrete nutrients that could be used by microorganisms for their growth. Gonçalves D. *et al.* have shown that FLAs secrete extracellular vesicles containing free fatty acids (47). It is known that *Candida* species can use

fatty acids as a source of carbon (48,49). The lysis of these extracellular vesicles could enrich the medium and be a source of nutrients.

As regards co-culture experiments, behavior of *C. albicans* is consistent with what has already been described. Steenbergen *et al.* (37) observed that with an initial inoculum of 10^5 *C. albicans*/mL co-cultured with *A. castellanii*, no yeasts survived for 48 hours. In our experiment, when *C. albicans* was co-cultured with *A. castellanii* trophozoites, there was also a rapid decrease in the number of CFU/mL, and no yeasts were found at 168 h. However, with *A. castellanii* supernatant, *C. albicans* was able to survive and proliferate. This data support the ability of *A. castellanii* to phagocyte and digest *C. albicans*. Phagocytosis has been recognized as an important feeding mechanism for FLA (50,51). *A. castellanii* feeds on various microorganisms such as bacteria (52) or yeasts such as *Saccharomyces cerevisiae* (37). Yeast walls are mainly composed of mannose polymers (53). Due to mannose receptors, FLAs are able to recognize and trigger yeast phagocytosis (54). However, phagolysosome effectiveness in destroying yeast could differ between two species of FLA. In our study, when *C. albicans* is co-cultured with *V. vermiformis* trophozoites, no yeast decrease occurred. Barbot *et al.* (36), also observed by TEM that *C. albicans* was internalized unaltered in *V. vermiformis* trophozoites. *V. vermiformis* seemed not able to digest *C. albicans*. It has been noted that *Acanthamoeba* genus present relatively simple nutritional requirements and can be grown in a wide variety of media, unlike the genus *Vermamoeba*, which has more complex nutritional requirements (55). Capacity of microorganism digestion of this two FLA species may be different and could explain the difference in *Candida* phagocytosis. For example, N-acetyl muramidase, involved in bacteriolysis, differs between the two FLA species (56).

In contrast to *C. albicans*, in cocultures with *A. castellanii* or *V. vermiformis*, *C. auris* could survive up to 168 h, even though internalization was observed in both FLA species (Figure 5). There was significant proliferation between 48 h and 120 h of incubation under each condition. Thus, unlike *C. albicans*, *C. auris* presented some capacity to resist destruction by both FLA species. It could be one of the microorganisms, such as several bacteria, which have evolved as to be resistant to FLA predation. These bacteria are collectively referred to as amoeba-resistant bacteria (28). For *Cryptococcus neoformans*, another yeast, normally destroyed by *Acanthamoeba polyphaga* (57), several strains have evolved to resist destruction by FLA (58). Steenbergen *et al.* showed that *C. neoformans* developed a capacity for non-lytic exocytosis by modification of their capsule (59,60). Another example is *L. monocytogenes*,

which, in order to disrupt the phagosomal membrane of phagocytic host cells, secretes listeriolysin and two phospholipases C (61). This bacteria can thereby survive predation by *A. castellanii* (62). *Mycobacterium llatzerense*, a non-tuberculous environmental mycobacterium remains viable and capable of growing by inhibiting phagosomal acidification despite internalization into *A. castellanii* by phagocytosis (63). Observations by Samba-Louaka *et al.* in 2018 (64), suggested that *Mycobacterium avium* could also block the acidification process of the phagosomes of *A. castellanii*. *C. auris* could employ similar resistance mechanisms to escape phagocytic destruction by FLA. This is corroborated by TEM that show the internalization of intact yeasts in the vacuoles of the two FLA species (Figure 5).

In the environment, FLAs are found mainly in water biofilms. Due to beneficial interaction with several bacteria, they act as reservoirs for these pathogens resulting in protection against hostile conditions and promoting bacterial spread in the environment (28,65,66). The mechanism could be the same for *C. auris*. In this case, the external environment where FLAs are present, especially water, could represent an ecological niche for *C. auris*. Moreover, FLA in hospital water systems raises the question of a potential infectious source. Management of hot water contamination systems is a major issue in the control of public health risks. FLA leads to major problems of physical and chemical resistance to the treatments used in water networks, whether with *Acanthamoeba sp.* (67,68) or *Vermamoeba sp.* (69). *C. auris* could benefit from physical protection and colonize water systems.

FLAs can increase internalized microorganisms' virulence, one example being *L. pneumophila*. In 1980, Rowbotham *et al.* published the first report on the intracellular multiplication of *L. pneumophila* in *Acanthamoeba spp.* and *Naegleria spp.* (70). They showed that intracellular growth within protozoa led to *L. pneumophila* being more able to infect human monocytes (71), particularly by inducing phenotypic modulation (72). These strains were also more resistant to chemical disinfectants, biocides and antibiotics (73,74). Steenbergen JN *et al.* showed that FLA could play a key role in the selection and maintenance of fungal virulence (37). Selection of virulent strains could consequently apply to *C. auris* in the environment, due to the positive interaction with FLA.

In conclusion, we showed that there are positive interactions between *C. auris* and FLA. This is particularly beneficial to *C. auris*, which is able to survive and proliferate in poor environments, probably thanks to diffusible molecules secreted by FLA. There is also physical interaction with internalization of the yeast within the amoeba that could protect it. *A. castellanii*

and *V. vermiformis* being frequently found in outdoor environments and hospital water systems (19,27), hospital tap water could therefore represent a source of contamination with *C. auris* through FLA protection, which would necessitate increased monitoring of the hospital water destined to immunocompromised patients. Fungal and protozoal behaviors could be studied under other conditions (temperature, disinfectants) to continue to explore the presence of *C. auris* in hospital environments.

Acknowledgements

We thank Jeffrey Arsham for English-language revision.

References

1. Kullberg BJ, Arendrup MC. Invasive *Candidiasis*. Campion EW, editor. N Engl J Med. 2015 Oct 8;373(15):1445–56.
2. Arendrup MC, Sulim S, Holm A, Nielsen L, Nielsen SD, Knudsen JD, et al. Diagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia. J Clin Microbiol. 2011 Sep;49(9):3300–8.
3. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients. Antimicrob Agents Chemother. 2011 Feb;55(2):532–8.
4. Cortegiani A, Misseri G, Chowdhary A. What's new on emerging resistant *Candida* species. Intensive Care Med. 2019 Apr;45(4):512–5.
5. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. *Candida auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiology and Immunology. 2009;53(1):41–4.
6. Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. First Three Reported Cases of Nosocomial Fungemia Caused by *Candida auris*. J Clin Microbiol. 2011 Sep;49(9):3139–42.
7. Chowdhary A, Sharma C, Meis JF. *Candida auris*: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. Hogan DA, editor. PLoS Pathog. 2017 May 18;13(5):e1006290.
8. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, et al. Investigation of the First Seven Reported Cases of *Candida auris*, a Globally Emerging Invasive, Multidrug-Resistant Fungus—United States, May 2013–August 2016. American Journal of Transplantation. 2017;17(1):296–9.
9. Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015 Feb 1;41(2):285–95.
10. Ruiz-Gaitán A, Moret AM, Tásias-Pitarch M, Aleixandre-López AI, Martínez-Morel H, Calabuig E, et al. An outbreak due to *Candida auris* with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses. 2018;61(7):498–505.
11. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous Emergence of Multidrug-Resistant *Candida auris* on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis. 2017 Jan 15;64(2):134–40.

12. Arendrup MC, Patterson TF. Multidrug-Resistant *Candida*: Epidemiology, Molecular Mechanisms, and Treatment. *The Journal of Infectious Diseases*. 2017 Aug 15;216(suppl_3):S445–51.
13. Mizusawa M, Miller H, Green R, Lee R, Durante M, Perkins R, et al. Can Multidrug-Resistant *Candida auris* Be Reliably Identified in Clinical Microbiology Laboratories? *J Clin Microbiol*. 2017 Feb;55(2):638–40.
14. Bao JR, Master RN, Azad KN, Schwab DA, Clark RB, Jones RS, et al. Rapid, Accurate Identification of *Candida auris* by Using a Novel Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry (MALDI-TOF MS) Database (Library). *Journal of Clinical Microbiology*. 2018 Apr 1;56(4):e01700-17.
15. Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, et al. First hospital outbreak of the globally emerging *Candida auris* in a European hospital. *Antimicrob Resist Infect Control*. 2016;5:35.
16. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast *Candida auris* on a Plastic Health Care Surface. *J Clin Microbiol*. 2017 Oct;55(10):2996–3005.
17. Cadnum JL, Shaikh AA, Piedrahita CT, Sankar T, Jencson AL, Larkin EL, et al. Effectiveness of Disinfectants Against *Candida auris* and Other *Candida* Species. *Infection Control & Hospital Epidemiology*. 2017 Oct;38(10):1240–3.
18. Infection Prevention and Control for *Candida auris* | *Candida auris* | Fungal Diseases | CDC [Internet]. 2020 [cited 2020 Feb 16]. Available from: <https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html>
19. Thomas V, Herrera-Rimann K, Blanc DS, Greub G. Biodiversity of Amoebae and Amoeba-Resisting Bacteria in a Hospital Water Network. *Appl Environ Microbiol*. 2006 Apr;72(4):2428–38.
20. Trabelsi H, Sellami A, Dendena F, Sellami H, Cheikh-Rouhou F, Makni F, et al. Free-living Amoebae (FLA): morphological and molecular identification of *Acanthamoeba* in dental unit water. *Parasite*. 2010 Mar;17(1):67–70.
21. Marciano-Cabral F, Cabral G. *Acanthamoeba spp.* as Agents of Disease in Humans. *Clinical Microbiology Reviews*. 2003 Apr 1;16(2):273–307.
22. Fouque E, Héchard Y, Hartemann P, Humeau P, Trouilhé M-C. Sensitivity of *Vermamoeba* (*Hartmannella*) *vermiformis* cysts to conventional disinfectants and protease. *J Water Health*. 2015 Jun;13(2):302–10.
23. Rivera F, Rosas I, Castillo M, Chávez M, Gómez R, Chío RE, et al. Pathogenic and free-living protozoa cultured from the nasopharyngeal and oral regions of dental patients: II. *Environmental Research*. 1986 Apr;39(2):364–71.
24. Lorenzo-Morales J, Khan NA, Walochnik J. An update on *Acanthamoeba* keratitis: diagnosis, pathogenesis and treatment. *Parasite*. 2015;22:10.

25. Nazar M, Haghighi A, Taghipour N, Ortega-Rivas A, Tahvildar-Biderouni F, Mojarad EN, et al. Molecular identification of *Hartmannella vermiformis* and *Vannella persistens* from man-made recreational water environments, Tehran, Iran. *Parasitol Res.* 2012 Aug 1;111(2):835–9.
26. Montalbano Di Filippo M, Santoro M, Lovreglio P, Monno R, Capolongo C, Calia C, et al. Isolation and Molecular Characterization of Free-Living Amoebae from Different Water Sources in Italy. *International Journal of Environmental Research and Public Health.* 2015 Apr;12(4):3417–27.
27. Pagnier I, Valles C, Raoult D, La Scola B. Isolation of *Vermamoeba vermiformis* and associated bacteria in hospital water. *Microbial Pathogenesis.* 2015 Mar 1;80:14–20.
28. Greub G, Raoult D. Microorganisms Resistant to Free-Living Amoebae. *Clinical Microbiology Reviews.* 2004 Apr 1;17(2):413–33.
29. Barbot V, Robert A, Rodier M-H, Imbert C. Update on infectious risks associated with dental unit waterlines. *FEMS Immunol Med Microbiol.* 2012 Jul;65(2):196–204.
30. Fiore AE, Butler JC, Emori TG, Gaynes RP. A Survey of Methods Used to Detect Nosocomial Legionellosis Among Participants in the National Nosocomial Infections Surveillance System. *Infection Control & Hospital Epidemiology.* 1999 Jun;20(6):412–6.
31. Atlas RM, Williams JF, Huntington MK. *Legionella* contamination of dental-unit waters. *Appl Environ Microbiol.* 1995 Apr 1;61(4):1208–13.
32. Lohr DC, Goeken JA, Doty DB, Donta ST. *Mycobacterium gordonae* Infection of a Prosthetic Aortic Valve. *JAMA.* 1978 Apr 14;239(15):1528–30.
33. Philippe C, Blech M, Hartemann P. Intra-amoebal development of *Legionella pneumophila* and the potential role of amoebae in the transmission of Legionnaires' disease. *Med Mal Infect.* 2006 Feb 3;36(4):196–200.
34. Shen Y, Huang C, Lin J, Wu W, Ashbolt NJ, Liu W-T, et al. Effect of Disinfectant Exposure on *Legionella pneumophila* Associated with Simulated Drinking Water Biofilms: Release, Inactivation, and Infectivity. *Environ Sci Technol.* 2017 21;51(4):2087–95.
35. Cunha BA, Burillo A, Bouza E. Legionnaires' disease. *The Lancet.* 2016 Jan 23;387(10016):376–85.
36. Barbot V, Migeot V, Quellard N, Rodier M-H, Imbert C. *Hartmannella vermiformis* can promote proliferation of *Candida* spp. in tap-water. *Water Research.* 2012 Nov;46(17):5707–14.
37. Steenbergen JN, Nosanchuk JD, Malliaris SD, Casadevall A. Interaction of *Blastomyces dermatitidis*, *Sporothrix schenckii*, and *Histoplasma capsulatum* with *Acanthamoeba castellanii*. *Infection and Immunity.* 2004 Jun 1;72(6):3478–88.

38. Schuster FL. Cultivation of pathogenic and opportunistic free-living amebas. Clin Microbiol Rev. 2002 Jul;15(3):342–54.
39. Abd H, Wretling B, Saeed A, Idsund E, Hultenby K, Sandstrå M G. *Pseudomonas aeruginosa* Utilises Its Type III Secretion System to Kill the Free-Living Amoeba *Acanthamoeba castellanii*. Journal of Eukaryotic Microbiology. 2008 May 6;55(3):235–43.
40. Groscop JA, Brent MM. The effects of selected strains of pigmented microorganisms on small free-living amoebae. Can J Microbiol. 1964 Aug 1;10(4):579–84.
41. Sherry L, Ramage G, Kean R, Borman A, Johnson EM, Richardson MD, et al. Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant *Candida auris*. Emerg Infect Dis. 2017 Feb;23(2):328–31.
42. Munusamy K, Vadivelu J, Tay ST. A study on *Candida* biofilm growth characteristics and its susceptibility to aureobasidin A. Rev Iberoam Micol. 2018 Jun;35(2):68–72.
43. Douesnard-Malo F, Daigle F. Increased Persistence of *Salmonella enterica* Serovar Typhi in the Presence of *Acanthamoeba castellanii*. Appl Environ Microbiol. 2011 Nov;77(21):7640–6.
44. Cateau E, Verdon J, Fernandez B, Hechard Y, Rodier M-H. *Acanthamoeba* sp. promotes the survival and growth of *Acinetobacter baumannii*. FEMS Microbiol Lett. 2011 Jun 1;319(1):19–25.
45. Lamrabet O, Medie FM, Drancourt M. *Acanthamoeba polyphaga*-Enhanced Growth of *Mycobacterium smegmatis*. PLOS ONE. 2012 Jan 11;7(1):e29833.
46. Cateau E, Hechard Y, Fernandez B, Rodier MH. Free living amoebae could enhance *Fusarium oxysporum* growth. Fungal Ecology. 2014 Apr 1;8:12–7.
47. Gonçalves D de S, Ferreira M da S, Liedke SC, Gomes KX, de Oliveira GA, Leão PEL, et al. Extracellular vesicles and vesicle-free secretome of the protozoa *Acanthamoeba castellanii* under homeostasis and nutritional stress and their damaging potential to host cells. Virulence. 2018 31;9(1):818–36.
48. Piekarska K, Mol E, Berg M van den, Hardy G, Burg J van den, Roermund C van, et al. Peroxisomal Fatty Acid β -Oxidation Is Not Essential for Virulence of *Candida albicans*. Eukaryotic Cell. 2006 Nov 1;5(11):1847–56.
49. Eschenfeldt WH, Zhang Y, Samaha H, Stols L, Eirich LD, Wilson CR, et al. Transformation of Fatty Acids Catalyzed by Cytochrome P450 Monooxygenase Enzymes of *Candida tropicalis*. Appl Environ Microbiol. 2003 Oct 1;69(10):5992–9.
50. Bowers B. Comparison of pinocytosis and phagocytosis in *Acanthamoeba castellanii*. Experimental Cell Research. 1977 Dec 1;110(2):409–17.
51. Rodríguez-Zaragoza S. Ecology of Free-Living Amoebae. Critical Reviews in Microbiology. 1994 Jan;20(3):225–41.

52. De Moraes J, Alfieri SC. Growth, encystment and survival of *Acanthamoeba castellanii* grazing on different bacteria. FEMS Microbiol Ecol. 2008 Nov 1;66(2):221–9.
53. Nakajima T, Ballou CE. Characterization of the Carbohydrate Fragments Obtained from *Saccharomyces cerevisiae* Mannan by Alkaline Degradation. J Biol Chem. 1974 Oct 12;249(23):7679–84.
54. Allen PG, Dawidowicz EA. Phagocytosis in *Acanthamoeba*: I. A mannose receptor is responsible for the binding and phagocytosis of yeast. J Cell Physiol. 1990 Dec;145(3):508–13.
55. Visvesvara GS, Balamuth W. Comparative Studies on Related Free-Living and Pathogenic Amebae With Special Reference to *Acanthamoeba*. The Journal of Protozoology. 1975 May;22(2):245–56.
56. Weekers PHH, Engelberts AMW, Vogels GD. Bacteriolytic activities of the free-living soil amoebae, *Acanthamoeba castellanii*, *Acanthamoeba polyphaga* and *Hartmannella vermiformis*. Antonie van Leeuwenhoek. 1995 Oct;68(3):237–43.
57. Bunting LA, Neilson JB, Bulmer GS. *Cryptococcus neoformans*: gastronomic delight of a soil ameba. Sabouraudia. 1979 Sep;17(3):225–32.
58. Neilson JB, Ivey MH, Bulmer GS. *Cryptococcus neoformans*: pseudohyphal forms surviving culture with *Acanthamoeba polyphaga*. Infection and Immunity. 1978;20(1):262–6.
59. Steenbergen JN, Shuman HA, Casadevall A. *Cryptococcus neoformans* interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci USA. 2001 Dec 18;98(26):15245–50.
60. Chrisman CJ, Albuquerque P, Guimaraes AJ, Nieves E, Casadevall A. Phospholipids trigger *Cryptococcus neoformans* capsular enlargement during interactions with amoebae and macrophages. Hull CM, editor. PLoS Pathog. 2011 May 26;7(5):e1002047.
61. Goetz M, Bubert A, Wang G, Chico-Calero I, Vazquez-Boland J-A, Beck M, et al. Microinjection and growth of bacteria in the cytosol of mammalian host cells. Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12221–6.
62. Zhou X, Elmore J, Call DR. Interactions between the environmental pathogen *Listeria monocytogenes* and a free-living protozoan (*Acanthamoeba castellanii*). Environ Microbiol. 2007 Apr;9(4):913–22.
63. Delafont V, Samba-Louaka A, Cambau E, Bouchon D, Moulin L, Héchard Y. *Mycobacterium llatzerense*, a waterborne *Mycobacterium*, that resists phagocytosis by *Acanthamoeba castellanii*. Sci Rep. 2017 May;7(1):46270.
64. Samba-Louaka A, Robino E, Cochard T, Branger M, Delafont V, Aucher W, et al. Environmental *Mycobacterium avium* subsp. *paratuberculosis* Hosted by Free-Living Amoebae. Front Cell Infect Microbiol. 2018 Feb 9;8:28.

65. Thomas V, McDonnell G, Denyer SP, Maillard J-Y. Free-living amoebae and their intracellular pathogenic microorganisms: risks for water quality. *FEMS Microbiol Rev.* 2010 May;34(3):231–59.
66. Horn M, Wagner M, Müller K-D, Schmid EN, Fritsche TR, Schleifer K-H, et al. *Neochlamydia hartmannellae* gen. nov., sp. nov. (Parachlamydiaceae), an endoparasite of the amoeba *Hartmannella vermiformis*. *Microbiology.* 2000;146(5):1231–9.
67. Sutherland EE, Berk SG. Survival of protozoa in cooling tower biocides. *Journal of Industrial Microbiology.* 1996 Jan;16(1):73–8.
68. Critchley M, Bentham R. The efficacy of biocides and other chemical additives in cooling water systems in the control of amoebae. *Journal of Applied Microbiology.* 2009 Mar;106(3):784–9.
69. Kuchta JM, Navratil JS, Shepherd ME, Wadowsky RM, Dowling JN, States SJ, et al. Impact of chlorine and heat on the survival of *Hartmannella vermiformis* and subsequent growth of *Legionella pneumophila*. *Applied and Environmental Microbiology.* 1993;59(12):4096–100.
70. Rowbotham TJ. Preliminary report on the pathogenicity of *Legionella pneumophila* for freshwater and soil amoebae. *J Clin Pathol.* 1980 Dec;33(12):1179–83.
71. Cirillo JD, Falkow S, Tompkins LS. Growth of *Legionella pneumophila* in *Acanthamoeba castellanii* enhances invasion. *Infect Immun.* 1994 Aug;62(8):3254–61.
72. Barker J, Lambert PA, Brown MR. Influence of intra-amoebic and other growth conditions on the surface properties of *Legionella pneumophila*. *Infect Immun.* 1993 Aug;61(8):3503–10.
73. Barker J, Brown MR, Collier PJ, Farrell I, Gilbert P. Relationship between *Legionella pneumophila* and *Acanthamoeba polyphaga*: physiological status and susceptibility to chemical inactivation. *Appl Environ Microbiol.* 1992 Aug;58(8):2420–5.
74. Barker J, Scaife H, Brown MR. Intraphagocytic growth induces an antibiotic-resistant phenotype of *Legionella pneumophila*. *Antimicrob Agents Chemother.* 1995 Dec;39(12):2684–8.

Résumé

Les levures du genre *Candida* sont responsables d'infections graves chez les patients immunodéprimés. Parmi celles-ci, *Candida auris* est une espèce émergente découverte en 2009 ayant causé plusieurs épidémies dans le monde. Sa capacité à devenir résistante aux différentes classes d'antifongiques systémiques, les difficultés liées à son identification et son aptitude à persister en milieu hospitalier en font un problème de santé publique. Actuellement, les données sur le réservoir environnemental de *C. auris* sont limitées alors qu'elles sont essentielles afin de contrôler sa propagation. Le but de notre étude était d'explorer les interactions entre *C. auris* et deux espèces d'amibes libres, potentiellement présentes dans le même environnement hydrique.

C. auris a été incubé à 37°C avec des trophozoïtes d'*Acanthamoeba castellanii* ou de *Vermamoeba vermiformis*, ou avec leurs surnageants de culture, dans de l'eau filtrée issue du réseau hospitalier. Le nombre de trophozoïtes d'amibes et de levures a été déterminé à 48 h, 120 h et 168 h de coculture. De la microscopie électronique à transmission (MET) a été effectuée à 48 h de coculture. Afin de comparer les résultats avec une autre espèce de *Candida*, les mêmes expériences de coculture ont été réalisées avec *Candida albicans*.

Alors que *C. albicans* et *C. auris* n'ont pas pu survivre seules dans l'eau, les surnageants des deux espèces d'amibes libres ont favorisé la survie et la prolifération des levures. *C. albicans* a été détruit par les trophozoïtes d'*A. castellanii* mais a survécu en présence des trophozoïtes de *V. vermiformis*. Contrairement à *C. albicans*, *C. auris* a pu survivre et proliférer au contact des trophozoïtes d'*A. castellanii* ou de *V. vermiformis*. L'internalisation de *C. auris* au sein des deux espèces d'amibes libres a également été observée par MET.

Un réservoir environnemental hydrique de *C. auris* peut donc être envisagé en lien avec les amibes libres. De plus, du fait de la présence de ces amibes dans les réseaux d'eau hospitaliers, leur contamination par *C. auris* serait possible.

Mots-clés: *Candida auris* ; amibes libres ; réseaux d'eau hospitaliers ; épidémies

SERMENT



En présence des Maîtres de cette école, de mes chers condisciples et devant l'effigie d'Hippocrate, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité dans l'exercice de la médecine. Je donnerai mes soins gratuits à l'indigent et n'exigerai jamais un salaire au-dessus de mon travail. Admis dans l'intérieur des maisons mes yeux ne verront pas ce qui s'y passe ; ma langue taira les secrets qui me seront confiés, et mon état ne servira pas à corrompre les mœurs ni à favoriser le crime. Respectueux et reconnaissant envers mes Maîtres, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères.

Que les hommes m'accordent leur estime si je suis fidèle à mes promesses ! Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque !

